Gilead Sciences (NASDAQ:GILD) Shares Unloaded Rep. Josh Gottheimer

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Gilead Sciences, Inc. NASDAQ: GILD. In a filing disclosed on June 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Gilead Sciences stock on May 14th. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/25/2025.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 6/25/2025.
• Sold $1,001 - $15,000 in shares of ConocoPhillips NYSE: COP on 6/24/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 6/24/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/24/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/20/2025.
• Purchased $1,001 - $15,000 in shares of Cloudflare NYSE: NET on 6/20/2025.
• Purchased $1,001 - $15,000 in shares of Carvana NYSE: CVNA on 6/20/2025.
• Sold $1,001 - $15,000 in shares of McDonald's NYSE: MCD on 6/20/2025.

Gilead Sciences Trading Up 2.7%

Shares of GILD traded up $3.00 on Friday, hitting $116.20. 7,677,220 shares of the stock traded hands, compared to its average volume of 5,825,949. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The firm has a market capitalization of $144.54 billion, a P/E ratio of 24.46, a P/E/G ratio of 0.72 and a beta of 0.29. The stock's 50 day moving average is $109.91 and its two-hundred day moving average is $105.88. Gilead Sciences, Inc. has a 1 year low of $72.43 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the prior year, the business posted ($1.32) earnings per share. Gilead Sciences's revenue for the quarter was down .3% compared to the same quarter last year. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds have recently made changes to their positions in GILD. Brighton Jones LLC boosted its holdings in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after buying an additional 2,450 shares during the period. Golden State Wealth Management LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth about $70,000. Kestra Private Wealth Services LLC boosted its holdings in shares of Gilead Sciences by 4.4% in the fourth quarter. Kestra Private Wealth Services LLC now owns 29,368 shares of the biopharmaceutical company's stock worth $2,713,000 after buying an additional 1,247 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in shares of Gilead Sciences in the fourth quarter worth about $33,000. Finally, Angeles Wealth Management LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth about $200,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on GILD. Oppenheimer dropped their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target for the company. Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Finally, Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research report on Friday. Eight equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $112.36.

Insider Activity

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the sale, the insider owned 121,152 shares of the company's stock, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,000 shares of company stock valued at $7,844,775. Corporate insiders own 0.27% of the company's stock.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.